GLP-1semaglutidechronic kidney diseaseflow trialtgaaustralia

Australian panel issues semaglutide guidance for type 2 diabetes with chronic kidney disease

The multidisciplinary review sets out TGA indications, PBS restrictions and sequencing of GLP-1 receptor agonists alongside RAAS blockade, SGLT2 inhibitors and finerenone.

By Maren Holt · Senior Reporter, GLP-1

Sep 29 20:00 ETSource: Internal medicine journal

The wire

01Writing in the Internal Medicine Journal, the panel builds on FLOW, in which once-weekly semaglutide 1 mg cut major kidney disease events 24%, major adverse cardiovascular events 18% and all-cause mortality 20% versus placebo.
02Prescribers get practical sequencing advice and priority groups, including residual albuminuria, HFpEF, established cardiovascular disease, obesity and Aboriginal and Torres Strait Islander people at high cardiorenal risk.
03The authors flag evidence gaps in non-diabetic CKD, advanced CKD, dialysis and transplant populations, and note access barriers under PBS restrictions.

From the source

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel
Internal medicine journal · 2026 Sep 30 · Pedagogos E, Chen R, Nelson A et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42813318/